Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 20/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 20/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 15/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900829 | 0.80 | MAPT (0.47) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL7305374 | 0.73 | SMN1; SMN2 (0.40) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL9682398 | 0.69 | KCNJ3 (0.43) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL25400204 | 0.69 | KCNJ3 (0.45) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL287415 | 0.68 | NOTUM (0.41) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL9681838 | 0.68 | KCNJ6 (0.40) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL3060712 | 0.68 | KCNJ6 (0.42) | KCNJ6KCNJ3KCNJ5 | |
| Hydrochloric Acid SCHEMBL9681843 | 0.68 | KCNJ3 (0.42) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL12829947 | 0.68 | MAPT (0.50) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL11701379 | 0.67 | MAPT (0.45) | KCNJ6KCNJ3KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KCNJ6 1306/4885KCNJ3 1553/4885KCNJ5 1302/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KCNJ6 1306/4885KCNJ3 1553/4885KCNJ5 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.